dc.creatorSalas, Patricio
dc.creatorSolovera, Maria Eliana
dc.creatorBannura, Felipe
dc.creatorMuñoz-Medel, Matias
dc.creatorCordova-Delgado, Miguel
dc.creatorSanchez, Cesar
dc.creatorIbañez, Carolina
dc.creatorGarrido, Marcelo
dc.creatorKoch, Erica
dc.creatorAcevedo, Francisco
dc.creatorMondaca, Sebastian
dc.creatorNervi, Bruno
dc.creatorMadrid, Jorge
dc.creatorPeña, Jose
dc.creatorPinto, Mauricio P.
dc.creatorValbuena, José
dc.creatorGalindo, Hector
dc.date.accessioned2024-01-19T18:21:49Z
dc.date.available2024-01-19T18:21:49Z
dc.date.created2024-01-19T18:21:49Z
dc.date.issued2021
dc.identifier10.3332/ecancer.2021.1201
dc.identifierhttp://dx.doi.org/10.3332/ecancer.2021.1201
dc.identifierhttps://repositorio.uc.cl/handle/11534/80804
dc.description.abstractBackground: Thymic epithelial tumours are rare and highly heterogeneous. Reports from the United States suggest an overall incidence of 0.15 per 100,000/year. In contrast, the incidence of these tumours in Latin America is largely unknown and reports are scarce, somewhat limited to case reports. Methods: Herein, we report a series of 38 thymic tumours from a single institution, retrospectively incorporated into this study. Patient characteristics and outcomes including age, sex, stage, paraneoplastic syndromes, treatment regimens and the date of decease were obtained from medical records. Results: Most cases in our series were females and young age (<50 years old) and early stage by Masaoka-Koga or the Moran staging systems. Also, a 34% of patients had myasthenia gravis (MG). Next, we analysed overall survival rates in our series and found that the quality of surgery (R0, R1 or R2), MG status and staging (Masaoka-Koga, Moran or TNM) were prognostic factors. Finally, we compared our data to larger thymic tumour series. Conclusions: Overall, our study confirms complete surgical resection as the standard, most effective treatment for thymic epithelial tumours. Also, the Masaoka-Koga staging system remains as a reliable prognostic factor but also the Moran staging system should be considered for thymomas.
dc.languageen
dc.rightsCC BY 3.0 DEED Attribution 3.0 Unported
dc.rightshttps://creativecommons.org/licenses/by/3.0/
dc.rightsacceso abierto
dc.subjectThymic tumour
dc.subjectThymoma
dc.subjectMyasthenia gravis
dc.subjectStaging
dc.titleOncological resection, myasthenia gravis and staging as prognostic factors in thymic tumours: a Chilean case series
dc.typeartículo


Este ítem pertenece a la siguiente institución